BRIC house

With the opening of its Moscow office in November, Burrill & Co. now has representation in, or near, all the BRIC countries, where G. Steven Burrill sees strong growth in the pharmaceutical market.

"To really be successful over the next 5-10 years you need a presence in markets that weren't historically important," Burrill told BioCentury. In a July 2012 report, IMS Health Inc. predicted that spending on pharmaceuticals in Brazil, Russia, India and China will grow 110% to $264 billion in 2016 from $126.6 billion in 2011...